JOURNAL OF CLINICAL IMMUNOLOGY, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal in the field of immunology, with an impressive standing as reflected in its Q1 ranking in both Immunology and Immunology and Allergy for 2023. With a history of publication dating back to 1981 and an E-ISSN of 1573-2592, this journal aims to disseminate cutting-edge research on diagnostic methods, therapeutic strategies, and understanding the mechanisms underlying immune responses. Its significant impact is underscored by its Scopus rankings, where it is placed in the top 15% of journals covering immunology and microbiology. The journal does not currently operate under an Open Access model, yet offers a robust platform for sharing essential findings that contribute to advancements in clinical immunology. As a resource for researchers, professionals, and students, the JOURNAL OF CLINICAL IMMUNOLOGY is pivotal in fostering dialogue and disseminating knowledge that enhances our understanding of immune-related diseases.

Cell Stem Cell, published by CELL PRESS, is a premier journal at the forefront of cellular biology, genetics, and molecular medicine. With an esteemed impact factor and recognized as a Q1 journal in multiple categories including Cell Biology, Genetics, and Molecular Medicine, it offers researchers, professionals, and students rigorous, peer-reviewed articles that shape the future of stem cell research and regenerative medicine. Located in Cambridge, MA, this journal has become an invaluable resource since its inception in 2007 and is committed to disseminating groundbreaking findings that drive innovation and understanding in these critical fields. By consistently ranking within the top percentile of its categories in Scopus, Cell Stem Cell remains an essential platform for scholarly communication, fostering collaboration among leading scientists worldwide. Although the journal does not currently offer open access options, its comprehensive insights are pivotal for anyone engaged in the study of stem cells and their applications.

Molecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.

CYTOTHERAPY is a distinguished journal published by Elsevier Science Ltd, focusing on the critical fields of cell therapy, transplantation, and regenerative medicine. Since its inception in 1999, the journal has established itself as a vital resource for researchers and practitioners, contributing significantly to advancements in Cancer Research, Cell Biology, Genetics, Immunology, and Oncology. With an impressive range of Q2 rankings across multiple categories and a remarkable Q1 standing in Transplantation for 2023, CYTOTHERAPY delivers high-impact research that addresses the evolving challenges in these fields. While the journal does not offer open access, it remains a reputable avenue for disseminating pivotal studies and reviews that push the boundaries of cell-based therapies. Researchers, clinicians, and students alike will find CYTOTHERAPY an indispensable platform to stay abreast of the latest discoveries and innovations that are shaping the future of medical science.

Immunotherapy, published by Future Medicine Ltd, is a leading journal focused on the evolving field of immunotherapy within the realms of immunology, oncology, and allergy. With an ISSN of 1750-743X and an E-ISSN of 1750-7448, this academic journal has been at the forefront of groundbreaking research since 2009, and continues to illuminating insights in a landscape critical for the development of innovative therapeutic strategies through 2024. Positioned within Q2 and Q3 quartiles in various relevant categories, the journal ranks commendably in Scopus metrics, exhibiting robust engagement and relevance in Oncology and Immunology. It serves as an essential resource for researchers, clinicians, and students eager to stay abreast of advancements in immunotherapy, while also providing an open platform for sharing impactful studies. By disseminating high-quality research, Immunotherapy fosters a global dialogue among professionals and contributes significantly to the scientific community's collective knowledge on the increasing role of immune-based therapies in disease management.

Molecular Therapy Nucleic Acids is a premier open-access journal published by CELL PRESS, dedicated to advancing the field of molecular medicine through the innovative application of nucleic acid-based therapies. Since its inception in 2012, this journal has become an essential resource for researchers and professionals in drug discovery and molecular medicine, reflected in its status as a Q1 journal in both categories for 2023. With a notable impact factor and high rankings in Scopus, including #8 out of 157 in Drug Discovery and #16 out of 178 in Molecular Medicine, it serves to disseminate groundbreaking research and foster collaborations among scientists worldwide. The journal's comprehensive scope encompasses a wide variety of topics, including gene therapy, RNA interference, and CRISPR technology, ensuring that it remains at the forefront of scientific excellence. With open access availability, Molecular Therapy Nucleic Acids actively promotes the widespread dissemination of knowledge, making its crucial insights accessible to students, researchers, and industry professionals alike.

Welcome to Molecular Neurobiology, the premier journal dedicated to the exploration of the molecular mechanisms underlying nervous system function and pathophysiology. Published by Springer, this journal provides an essential platform for disseminating high-quality research in the rapidly evolving fields of Cellular and Molecular Neuroscience and Neurology, boasting an impressive impact factor that reflects its esteemed position within the academic community. With its ranking in the Q1 and Q2 quartiles for various neuroscience categories, Molecular Neurobiology stands at the forefront of groundbreaking discoveries, showcasing innovative studies that bridge basic science and clinical application. Researchers and professionals are invited to contribute to its rich portfolio, which spans from fundamental insights into cellular processes to advanced therapeutic strategies. Although Molecular Neurobiology does not operate as an Open Access journal, its influential body of work remains accessible through institutional and personal subscriptions. As we converge from 1987 to 2024, we continue to aim for excellence, seeking to catalyze progress in understanding neurological diseases and enhance the scientific dialogue within the neuroscience community.

Human Gene Therapy, an esteemed journal published by Mary Ann Liebert, Inc., is at the forefront of the rapidly evolving fields of genetics, molecular biology, and molecular medicine. With a significant impact in its domain, it is categorized in the Q2 quartile across multiple disciplines, reflecting its commitment to disseminating high-quality, impactful research. Established in 1990, the journal has continuously provided a vital platform for scientists and practitioners to explore groundbreaking developments in gene therapy, genetic engineering, and related technologies. With a focus on peer-reviewed articles that foster advancements in therapeutic applications, Human Gene Therapy serves not only as a comprehensive resource for academia but also as an essential reference for professionals engaged in genetic research and clinical practice. Although currently not open access, the journal remains a crucial source of knowledge, driving innovation and collaboration within the gene therapy community.

Translational Stroke Research, published by Springer, stands at the forefront of the intersection of cardiology, neurology, and neuroscience, specifically focusing on the latest advancements in stroke research from 2010 to 2024. With an impressive impact factor as evidenced by its Q1 rankings in Cardiology and Cardiovascular Medicine, Clinical Neurology, and Neuroscience, this journal is a vital resource for researchers, clinicians, and students alike. It holds significant recognition in the academic community, achieving notable rankings in Scopus, including 15th out of 387 in Cardiology and 17th out of 400 in Clinical Neurology, showcasing its impact and relevance in these critical fields. Although not an open-access journal, it provides access options through institutional subscriptions, thereby facilitating the sharing of influential research that has the potential to shape the mitigation and understanding of stroke and related conditions. Researchers and practitioners seeking to expand their knowledge and engage with cutting-edge findings will find Translational Stroke Research to be an indispensable addition to their scholarly resources.

GENE THERAPY, published by SpringerNature, is a prestigious academic journal at the forefront of research in the fields of genetics, molecular biology, and molecular medicine. Since its inception in 1994, this journal has evolved into a vital resource for scholars, practitioners, and students, providing cutting-edge insights into gene therapy techniques and innovations. With an impressive impact factor reflecting its significant influence— ranking in the Q1 quartile across multiple categories in 2023—GENE THERAPY offers rigorous peer-reviewed articles that address both basic and applied aspects of gene therapy. The journal is recognized for its role in promoting advancements in therapeutic strategies, thus enhancing understanding of genetic disorders and treatment efficacy. Researchers will find this journal invaluable for publishing their findings, staying updated on the latest breakthroughs, and fostering interdisciplinary collaborations. Engage with the latest in gene therapy by accessing this influential platform, and contribute to a field that holds the potential to transform healthcare outcomes worldwide.